However, monotherapy with monoclonal antibodies against PD-1 and PD-L1 has shown limited effectiveness in the treatment of metastatic breast cancer, partly due to the low number of tumor-infiltrating lymphocytes in most breast cancers and the adverse effects they manifest in the metabolic pathways of immune cells. The gene discussed is PDCD1; the disease is neoplasm.